Nuclear medicine

Nuclear medicine is primarily concerned with functional imaging and 'molecular' therapy. Radiopharmaceuticals (radioactive drugs) are used for imaging, e.g. with positron emission tomography (PET), and for the treatment of pathogenic processes such as tumors, supported by computed tomography (CT) imaging if necessary to visualize anatomical structures.


Our range of services includes imaging with PET/CT, SPECT/CT (Single Photon Emission Computed Tomography) and scintigraphy of tumor diseases as well as diseases of the heart, thyroid, brain, kidneys and other organs.
We have established ourselves as a center for nuclear medicine therapies in Switzerland and play a leading role in the Center for Neuroendocrine and Endocrine Tumors, which has been awarded the status of "Center of Excellence" by the European Neuroendocrine Tumor Society (ENETS). With this in mind, we specialize in the treatment of neuroendocrine tumours (with an international reputation in this field), but also in the treatment of advanced, hormone-refractory prostate cancer, liver tumours and thyroid diseases.
Our patients have access to our own nuclear medicine ward with 9 beds.


Together with the Department of Endocrinology, Diabetology & Metabolism at the USB, we operate the interdisciplinary thyroid outpatient clinic for the diagnosis and treatment of thyroid diseases. We also work closely with the Department of Cardiology at the USB for PET/CT and SPECT/CT imaging of the heart of patients with coronary heart disease.
Our team consists of 11 doctors, 15 radiology specialists, 4 nurses and 3 administrative staff.

Our range of examinations extends from scintigraphy to fusion imaging in cross-sectional imaging. The fusion of nuclear medicine scintigrams with the morphological images from computer tomography (CT) is carried out in a single examination. We have state-of-the-art nuclear medicine equipment including SPECT/CT (Single Photon Emission Computed Tomography) and PET/CT (Positron Emission Tomography) at our disposal for all examinations.
The radioactive substances used for diagnostics and therapy are used in minimal quantities and in a very targeted manner. They primarily accumulate in the diseased organ and hardly affect the healthy tissue.

Our research focuses on the further development of the treatment of neuroendocrine tumors with radioactive peptides and on the development of new substances for the early detection and treatment of diseases. We offer lectures and courses as part of university teaching (human medicine). In addition, we are responsible for the further training of doctors and MTRAS in our specialist field and are authorized as a category A training centre in accordance with Swiss further training regulations for further training as a specialist in nuclear medicine.

In research, we are known for quickly adopting new developments in radiopharmacy into clinical routine for the benefit of our patients.

Our research focuses on the further development of diagnostics and the treatment of neuroendocrine tumors with radioactive peptides and on the development of new substances for the early detection and treatment of diseases:

Over the past 10 years, the Department of Radiopharmaceutical Chemistry has worked with us to develop several 68Ga-labeledtracers for PET (positron emission tomography) or PET/CT (combination of PET and computed tomography) imaging and evaluated them in patients. Two tracers developed at the University Hospital Basel, 68Ga-DOTATOCand 68Ga-DOTANOC, are now established PET tracers worldwide and have become the standard in the imaging of neuroendocrine tumors. The development of new 68Ga-basedPET tracers has great potential, particularly in clinical tumor diagnostics, and thus strengthens the university's focus on oncology.

The specific binding of radioactive substances to molecular target structures can also be used therapeutically. Radiopharmaceutical Chemistry at the University Hospital Basel was one of the first institutions worldwide to recognize this possibility and has developed various therapeutically effective radiotracers and evaluated them together with Nuclear Medicine over the last 15 years. Our most successful development was 90Y-DOTATOC/177Lu-DOTATOC. Today, 90Y-DOTATOC/177Lu-DOTATOCtherapyis the standard therapy for patients with neuroendocrine tumors. Due to our pioneering role and the unique position of 90Y-DOTATOC/177Lu-DOTATOC therapy, this service segment has been recognized as a top medical focus of the University Hospital since 2010.

We are currently planning clinical trials to further improve the imaging and treatment of patients with neuroendocrine tumors.

We offer our patients a specially equipped ward. This fulfills the statutory radiation protection requirements for nuclear medicine therapies.

The ward, which was renovated in 2018, is located at Petersgraben 4 on the 4th floor. There are five single rooms and two double rooms with a view of the park. The necessary shielding measures are invisibly integrated into the walls and doors.

Our patients are shielded, but are regularly monitored by the nursing staff - taking into account the radiation protection regulations - and checked for their well-being.

All rooms are equipped with:

  • WC and shower (with own waste water system)
  • WLAN
  • Television and radio
  • telephone

Nuclear medicine team

a1135ef1-deef-4082-a528-0ed735cae9bc

Prof. Dr. phil. Dr. med Damian Wild

Leitung Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

7682969d-f5c1-4dad-937c-0cc57b44ed48

Dr. Felix Kaul

Kaderarzt Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

1a11cc22-a07b-428e-b69b-2aa4fc13a97b

Dr. Guillaume Nicolas

Kaderarzt, Stv. Leitung Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

aea58208-1a95-4493-9d8e-f260cdd79150

PD Dr. Christof Rottenburger

Kaderarzt, stv. Leitung Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

4c77fc6b-ef59-4323-bf70-b153bde73091

Dr. Alin-Florin Chirindel

Oberarzt Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

505c022f-c4b7-49f4-bcf7-6e58c985b45b

Dr. Markus Löffler

Oberarzt Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

dfa66217-362b-43b4-a385-1d66ff60c33c

Dr. Najibullah Ahmadsei

Assistenzarzt Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

Dr. Felix Escher

Assistenzarzt Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

d66a9718-29f9-488c-a2ff-e7de445cfeb6

Dr. Julia Fricke

Assistenzärztin Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

b6d09c9c-a306-47a3-9467-d1e936ea4c0b

Dr. Abdulrafee Mushaweh

Assistenzarzt

Radiologie und Nuklearmedizin

Show profile

c210307a-ac0c-46d2-a8ca-b5046578ee2f

Dr. Catherine Regli-Fischer

Assistenzärztin Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

Dr. Felix Schmidt

Assistenzarzt Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

d5f0c122-515a-4ada-bbb3-33b62c6e8197

Dr. Kotryna Veresciagina

Assistenzärztin Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

Camilla-Aileen Wojsa

Assistenzärztin Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

72ff19d0-c95b-490d-8bc4-9d284d692afc

Aleksandra Zyrek

Assistenzärztin Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

e44aea58-be99-45e5-b364-bc480681c05c

Colombine Eisele

Studienkoordinatorin Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

2f182978-d91f-4372-a364-6ae748c48bb4

Lisa McDougall

Wissenschaftliche Mitarbeiterin radiopharmazeutische Chemie

Radiologie und Nuklearmedizin

Show profile

e63ab0ad-1c3c-455c-90cc-050027c1a668

Franziska Recher

Studienkoordinatorin Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

e384559b-d014-4d2a-b32d-e48ee965beda

Haris Hasanic

Teamleiter Radiologiefachpersonen Nuklearmedizin und BMAs radiopharmazeutische Chemie

Radiologie und Nuklearmedizin

Show profile

05a0aad8-d465-42f7-9bdd-1bb932092fa5

Mia Nagy

Leiterin Radiologiefachpersonen und BMAs

Radiologie und Nuklearmedizin

Show profile

05051447-8367-4dd4-874f-e69503b80dfd

Michelle Pintacoda

Leiterin Pflege Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

No data available

Diagnostics Tel. +41 61 328 66 81

Therapies Tel. +41 61 265 47 04

PET/CT Tel. +41 61 328 79 31

f6d4d530-0960-470d-a7d6-acbdbd7f4756

Arbesa Asani

Patientenmanagement Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

a2ab2862-b9ac-45ad-ab73-1bb31ecc0882

Brigit Avis-Furler

Assistentin Nuklearmedizin und radiopharmazeutische Chemie, Fachverantwortung Patientenmanagement Nuklearmedizin, Mitglied Tumorzentrum

Radiologie und Nuklearmedizin

Show profile

236a3df8-93a5-41de-b8a9-a94802cdfcc5

Gabriele Bertschi

Patientenmanagement Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

73eb24f8-988f-4efa-9cc9-d8a5fc3959ce

Christine Evard

Patientenmanagement Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile

6832b929-a7f3-4510-b3fa-41b60bec5301

Alfred Guggenbühl

Patientenmanagement Nuklearmedizin

Radiologie und Nuklearmedizin

Show profile